Fairvalue-Calculator Fairvalue-Calculator
EN DE

Island Pharmaceuticals Limited (ILA) Fair Value & Analysis

Healthcare · AU · Market cap A$109M

PriceA$0.3700
Fair ValueA$0.1100
Upside-70.3%
Quality92/100
Evidence: Low Range A$0.0800 – A$0.1400

Fair value as of: Jun 24, 2026

Analysis

Island Pharmaceuticals Limited (ILA) currently trades at A$0.3700, while our model-based Fair Value estimate is A$0.1100 — implying the stock looks roughly 70.3% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Island Pharmaceuticals Limited (ILA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of A$0.1100 versus a price of A$0.3700 — about −70% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ILA?
Our 21-model fair value for Island Pharmaceuticals Limited is A$0.1100 (as of Jun 24, 2026), built from audited fundamentals. The current price is A$0.3700.
What is the quality score of ILA?
Island Pharmaceuticals Limited has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.